Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine
Open Access
- 14 March 2007
- journal article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 5 (1), 16
- https://doi.org/10.1186/1479-5876-5-16
Abstract
Dendritic cells (DC) pulsed with tumor-derived antigenic material have widely been used in antitumor vaccination protocols. However, the optimal strategy of DC loading has not yet been established. Our aim was to define requirements of optimal DC vaccines in terms of in vivo protection in a murine B-cell lymphoma model. We compare various loading reagents including whole parental and modified tumor cells and a single tumor-specific antigen, namely the lymphoma idiotype (Id). Bone marrow-derived DC were pulsed in vitro and used for therapy of established A20 lymphomas. We show that a vaccine with superior antitumor efficacy can be generated when DC are loaded with whole modified tumor cells which provide both (i) antigenic polyvalency and (ii) receptor-mediated antigen internalization. Uptake of cellular material was greatly enhanced when the tumor cells used for DC pulsing were engineered to express an anti-Fc receptor immunoglobulin specificity. Upon transfer of these DC, established tumor burdens were eradicated in 50% of mice. By contrast, pulsing DC with unmodified lymphoma cells or with the lymphoma Id, even when it was endowed with the anti-Fc receptor binding arm, was far less effective. A specific humoral anti-Id response could be detected, particularly following delivery of Id protein-pulsed DC, but it was not predictive of tumor protection. Instead a T-cell response was pivotal for successful tumor protection. Interaction of the transferred DC with CD8+ T lymphocytes seemed to play a role for induction of the immune response but was dispensable when DC had received an additional maturation stimulus. Our analyses show that the advantages of specific antigen redirection and antigenic polyvalency can be combined to generate DC-based vaccines with superior antitumor efficacy. This mouse model may provide information for the standardization of DC-based vaccination protocols.Keywords
This publication has 34 references indexed in Scilit:
- Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor alphaPublished by Rockefeller University Press ,2018
- Optimizing the exogenous antigen loading of monocyte-derived dendritic cellsInternational Immunology, 2005
- In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell VaccinationThe Journal of Experimental Medicine, 2004
- Persistence of xenogenized vaccine cellsin vivoInternational Journal of Cancer, 2003
- B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunityCancer Gene Therapy, 2000
- Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cellsCancer Gene Therapy, 1999
- Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cellsGene Therapy, 1997
- Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.The Journal of Experimental Medicine, 1996
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991
- Enhanced antigen immunogenicity induced by bispecific antibodies.The Journal of Experimental Medicine, 1990